Welcome to our dedicated page for 20/20 Biolabs SEC filings (Ticker: AIDX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
20/20 BioLabs filings document the company's diagnostics business, public-company registration, operating results, and capital structure. Its registration statements describe the AIDX issuer as an emerging growth company and smaller reporting company, with disclosures covering the OneTest laboratory-testing business, risk factors, securities registration, and Nasdaq listing context.
Its Form 8-K reports cover material events such as financial-results announcements and financing arrangements, including secured convertible promissory notes and warrants. The filings also provide formal records of corporate governance, securities issuance, offering-related disclosures, and other matters associated with a commercial-stage diagnostics company operating a CAP-accredited and CLIA-licensed laboratory.
20/20 Biolabs, Inc. director John Woodson Rollins filed an initial ownership report showing direct holdings of several equity instruments in AIDX. He reports 13,029 shares of Series A Preferred Stock and 6,135 shares of Series A-2 Preferred Stock, each convertible into common stock on a one-for-one basis at his option and automatically if the common stock lists on a national exchange. He also holds multiple stock options, including grants for 48,780, 76,628, 37,584, 37,583, 30,000 and 30,000 shares of common stock, with vesting terms described in the notes, and 11,111 shares of common stock directly owned. The filing records existing positions rather than new purchases or sales.
20/20 Biolabs, Inc. filed Amendment No. 2 to its Form S-1 registration statement. This amendment is technical in nature and is being used primarily to file and organize exhibits listed in Item 16, such as charter documents, warrants, financing agreements, license agreements, and director and officer contracts.
The company states that the preliminary prospectus in Part I and the rest of Part II of the original registration statement remain unchanged and are omitted from this amendment. The filing also includes standard SEC undertakings about future post-effective amendments, liability, and indemnification, and is signed by Chief Executive Officer Jonathan Cohen and the company’s directors.